Pfizer has ceased development of its oral GLP-1 weight loss drug candidate, danuglipron, after a study participant “experienced potential drug-induced liver injury,” the company said April 14.
In dose-optimization studies, once-daily danuglipron met pharmacokinetic endpoints and showed potential for promising phase 3 trial results, Pfizer said. The drug’s frequency of liver enzyme elevations were also in-line with approved GLP-1s.
However, after an asymptomatic participant in one of the dose-optimization studies sustained a liver injury that resolved after discontinuing the drug, the company decided to axe the product.
“After a review of the totality of information, including all clinical data generated to date for danuglipron and recent input from regulators, Pfizer has decided to discontinue development of the molecule,” the company said.
Pfizer said it will continue developing its oral glucose-dependent insulinotropic polypeptide receptor candidate and other obesity treatments.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
